Neuroscience

CRISPR-ready neurons
#bit bio #CRISPR #Gene editing #Genetics / genomics #Neurology #Neuroscience

New CRISPR-ready neurons could democratise genomics

bit.bio has launched the first offering from its new product range ioCRISPR-Ready Cells, which allow research and drug discovery scientists to knockout any gene of interest in glutamatergic neurons. CRISPR-Ready ioGlutamatergic Neurons are first-in-class stem-cell derived human neurons containing a constitutively-expressed Cas9 nuclease for gene knockouts… Read More

#News

Neurons
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Discover the latest advances in neuroscience

Register now to join this unique online event. Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. You will hear from Fiona… Read More

Webinar date:
#News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

New online event: Innovative advances in neuroscience

Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. Join this free webinar to learn about innovation taking place… Read More

Webinar date:
#News

Parkinson's disease
#Gain Therapeutics #Genetics / genomics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Allosteric therapy targets common genetic cause of Parkinson’s

Gain Therapeutics has initiated a Phase I clinical trial of GT-02287, the company’s lead drug candidate for the treatment of GBA1 Parkinson’s disease. Preclinical data demonstrated that GT-02287 can restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which becomes misfolded and dysfunctional due to a… Read More

#News

CRISPR gene editing
#CRISPR #Funding #Genetics / genomics #National Institutes of Health (NIH) #Neuroscience #Yale University

NIH awards ‘bench-to-bedside’ grant for CRISPR drug development

The National Institutes of Health has awarded the first phase of a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases. The two diseases being targeted in the project are Angelman syndrome and H1-4… Read More

#News

Eye
#AMD #Drug targets #Louisiana State University #Neuroscience #Ophthalmology

Discovery provides new therapeutic approaches to AMD

New research suggests that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential – a discovery that may open new therapeutic avenues for AMD. The study shows that AMD decreases peripheral retinal docosahexaenoic… Read More

#News

Human brain
#Depression #Genetics / genomics #Korea #Major depressive disorder #Mouse models #Neuroscience

Researchers uncover molecular pathways underlying depression

Scientists have discovered the link between gene expression, DNA methylation, and brain structural changes in depression, revealing new potential therapeutic targets. By analysing gene interactions in mice subjected to behavioural tests, the researchers from Korea University Anam Hospital, Konkuk University, and Sahmyook University identified 141 genes… Read More

#News

DDW Neuroscience Guide
#Drug development #Drug discovery #Guide #Neurology #Neuroscience #Precision psychiatry

Unlocking neuroscience drug discovery

DDW has published the latest addition to its Guide Series, ‘Unlocking neuroscience drug discovery’. It covers the way the neuroscience sector is overcoming drug discovery challenges, advances in neuroscience and the era of precision neuroscience. Download to find out: Neuroscience drug discovery advances and challenges and how breakthroughs in this… Read More

#DDW eBooks #DDW Guides

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovative advances in neuroscience

In this webinar, hosted by DDW and sponsored by ACROBiosystems, you will learn about the innovative advances in neuroscience. You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at… Read More

Webinar date:
Sponsored by ACROBiosystems
#Webinars

Stephen Back and Philip Adeniyi, OHSU School of Medicine
#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience #Oregon Health & Science University

Scientists discover new target for Alzheimer’s drugs

Researchers have discovered a new avenue of cell death in Alzheimer’s disease and vascular dementia. A new study, led by scientists at Oregon Health & Science University (OHSU), has revealed that a form of cell death known as ferroptosis – caused by a build-up of iron… Read More

#Editor's Choice #News

Canary Wharf, London
#AviadoBio #Biotech hubs #Laboratory #London #London Innovation Centre #Neuroscience

Life sciences hub at Canary Wharf sees rapid growth

Kadans’ London Innovation Centre at Canary Wharf, London has launched its wet lab innovation and flexible workspace centre and welcomed a new tenant. AviadoBio, a gene therapy company developing medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. The… Read More

#News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week reflects the high level of interest and investment in… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Bayer #BlueRock Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Stem cells

Stem cell derived Parkinson’s therapy shows promise

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. BlueRock Therapeutics, a subsidiary of Bayer, has announced details of the positive data from a Phase I clinical trial for bemdaneprocel (BRT-DA01). The data were presented at… Read More

#News #Trending News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

This week in drug discovery (21-25 August)  

News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer. The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and… Read More

#News

Doctor administering a vaccine to patient
#Alzheimer's #Immune system #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience

Routine vaccines as effective as antibodies against Alzheimer’s

A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus… Read More

#News #Trending News

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Diana Spencer has chosen news stories this week which all discuss pre-clinical research studies… Read More

#News